17-BETA-CICLOPROPIL-(AMINO/OXI)-4-AZAESTEROIDES COMO INIBIDORES ACTIVOS DE 5-ALFA-REDUTASE E C17-C20-LIASE DE TESTOSTERONA

The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxyl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CYNTHIA A. GATES, PHILIPP M. WEINTRAUB, JAMES R. PRIBISH
Format:	Patent
Sprache:	por
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS STEROIDS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	CYNTHIA A. GATES PHILIPP M. WEINTRAUB JAMES R. PRIBISH
description	The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_PT880540EE</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PT880540EE</sourcerecordid><originalsourceid>FETCH-epo_espacenet_PT880540EE3</originalsourceid><addsrcrecordid>eNqFjMEKgkAQQL10iOob2mMdhqyUvI7rSAOrI-sW0UUktlOUYKe-PovunR4PHm8cvNY7SMkhaNZGKisVG1hgwaWs5MRLiADPSLUjK5xRrbQUorjklDOxg6N2fJRaZaRiQJMjWMoODmtSpPRw15sQDH98SNxwku-sxGkwura33s9-nATznJzeg-8eje-79uLv_tlULknCOAqJtv-LN4j_OOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>17-BETA-CICLOPROPIL-(AMINO/OXI)-4-AZAESTEROIDES COMO INIBIDORES ACTIVOS DE 5-ALFA-REDUTASE E C17-C20-LIASE DE TESTOSTERONA</title><source>esp@cenet</source><creator>CYNTHIA A. GATES ; PHILIPP M. WEINTRAUB ; JAMES R. PRIBISH</creator><creatorcontrib>CYNTHIA A. GATES ; PHILIPP M. WEINTRAUB ; JAMES R. PRIBISH</creatorcontrib><description>The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).</description><edition>7</edition><language>por</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; STEROIDS</subject><creationdate>2002</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20021031&DB=EPODOC&CC=PT&NR=880540E$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20021031&DB=EPODOC&CC=PT&NR=880540E$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>CYNTHIA A. GATES</creatorcontrib><creatorcontrib>PHILIPP M. WEINTRAUB</creatorcontrib><creatorcontrib>JAMES R. PRIBISH</creatorcontrib><title>17-BETA-CICLOPROPIL-(AMINO/OXI)-4-AZAESTEROIDES COMO INIBIDORES ACTIVOS DE 5-ALFA-REDUTASE E C17-C20-LIASE DE TESTOSTERONA</title><description>The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>STEROIDS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2002</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFjMEKgkAQQL10iOob2mMdhqyUvI7rSAOrI-sW0UUktlOUYKe-PovunR4PHm8cvNY7SMkhaNZGKisVG1hgwaWs5MRLiADPSLUjK5xRrbQUorjklDOxg6N2fJRaZaRiQJMjWMoODmtSpPRw15sQDH98SNxwku-sxGkwura33s9-nATznJzeg-8eje-79uLv_tlULknCOAqJtv-LN4j_OOA</recordid><startdate>20021031</startdate><enddate>20021031</enddate><creator>CYNTHIA A. GATES</creator><creator>PHILIPP M. WEINTRAUB</creator><creator>JAMES R. PRIBISH</creator><scope>EVB</scope></search><sort><creationdate>20021031</creationdate><title>17-BETA-CICLOPROPIL-(AMINO/OXI)-4-AZAESTEROIDES COMO INIBIDORES ACTIVOS DE 5-ALFA-REDUTASE E C17-C20-LIASE DE TESTOSTERONA</title><author>CYNTHIA A. GATES ; PHILIPP M. WEINTRAUB ; JAMES R. PRIBISH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_PT880540EE3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>por</language><creationdate>2002</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>STEROIDS</topic><toplevel>online_resources</toplevel><creatorcontrib>CYNTHIA A. GATES</creatorcontrib><creatorcontrib>PHILIPP M. WEINTRAUB</creatorcontrib><creatorcontrib>JAMES R. PRIBISH</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>CYNTHIA A. GATES</au><au>PHILIPP M. WEINTRAUB</au><au>JAMES R. PRIBISH</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>17-BETA-CICLOPROPIL-(AMINO/OXI)-4-AZAESTEROIDES COMO INIBIDORES ACTIVOS DE 5-ALFA-REDUTASE E C17-C20-LIASE DE TESTOSTERONA</title><date>2002-10-31</date><risdate>2002</risdate><abstract>The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5 alpha -reductase and C17 alpha -hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgen-dependent disorders also includes a combination therapy with known androgen-receptor antagonists, such as flutamide. The compounds of the invention have general formula (I).</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	por
recordid	cdi_epo_espacenet_PT880540EE
source	esp@cenet
subjects	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS STEROIDS
title	17-BETA-CICLOPROPIL-(AMINO/OXI)-4-AZAESTEROIDES COMO INIBIDORES ACTIVOS DE 5-ALFA-REDUTASE E C17-C20-LIASE DE TESTOSTERONA
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T20%3A08%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=CYNTHIA%20A.%20GATES&rft.date=2002-10-31&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EPT880540EE%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true